![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Cleary, G Mikus, A Somogyi and F Bochner
Department of Clinical and Experimental Pharmacology, University of Adelaide, Australia.
In the Sprague-Dawley (SD) rat, the O-demethylation of codeine to morphine is catalyzed by cytochrome P4502D1 (CYP2D1), which is absent in the female Dark Agouti (DA) rat. Oxycodone is similar in structure to codeine but, in contrast, has an analgesic potency in humans similar to morphine. The aim of the study was to test whether the DA rat and the SD rat pretreated with the CYP2D1 inhibitor quinine showed attenuation in analgesia to codeine and oxycodone. With the use of the tail flick model, dose-response curves were constructed to codeine, morphine, oxycodone and oxymorphone (the O-demethylated metabolite of oxycodone) in both rat strains. Codeine did not induce analgesia in the DA rat and there was a 60% reduction in codeine analgesia in the SD rat pretreated with quinine in comparison to the untreated SD rat. In the DA rat, the ED50 to oxycodone was increased 10-fold but there was a significant (P = .0001) prolongation in the duration of analgesia in comparison to that in the untreated SD rat. In the quinine-pretreated SD rat, there was no reduction in oxycodone analgesia but the duration of analgesia was also prolonged. It was concluded that 1) codeine- mediated analgesia requires the formation of morphine through the functional activity of CYP2D1 and 2) oxycodone-mediated analgesia may only be partly dependent on CYP2D1.
This article has been cited by other articles:
|
|
 |
|
  S. P. Hume, A. R. Lingford-Hughes, V. Nataf, E. Hirani, R. Ahmad, A. N. Davies, and D. J. Nutt Low Sensitivity of the Positron Emission Tomography Ligand [11C]Diprenorphine to Agonist Opiates J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 661 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Peckham and J. R. Traynor Comparison of the Antinociceptive Response to Morphine and Morphine-Like Compounds in Male and Female Sprague-Dawley Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1195 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lalovic, B. Phillips, L. L. Risler, W. Howald, and D. D. Shen QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES Drug Metab. Dispos., April 1, 2004; 32(4): 447 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Thompson, H. Wojno, E. Greiner, E. L. May, K. C. Rice, and D. E. Selley Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at {micro}- and {delta}-Opioid Receptors J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 547 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Williams, A. Patel, and R. F. Howard Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability Br. J. Anaesth., December 1, 2002; 89(6): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Williams, D. J. Hatch, and R. F. Howard Codeine phosphate in paediatric medicine Br. J. Anaesth., March 1, 2001; 86(3): 413 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Nielsen, F. B. Ross, and M. T. Smith Incomplete, Asymmetric, and Route-Dependent Cross-Tolerance between Oxycodone and Morphine in the Dark Agouti Rat J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 91 - 99. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. A. Bernard and E. Bruera Drug Interactions in Palliative Care J. Clin. Oncol., April 1, 2000; 18(8): 1780 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Mogil The genetic mediation of individual differences in sensitivity to pain and its inhibition PNAS, July 6, 1999; 96(14): 7744 - 7751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Tomkins, S. V. Otton, N. Joharchi, N-Y. Li, R. F. Balster, R. F. Tyndale, and E. M. Sellers Effect of Cytochrome P450 2D1 Inhibition on Hydrocodone Metabolism and its Behavioral Consequences in Rats J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1374 - 1382. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
